Eli Lilly wins FDA approval of donanemab for Alzheimer’s (NYSE:LLY)

The U.S. FDA has approved Eli Lilly’s (NYSE:LLY) donanemab as a treatment for early Alzheimer’s disease.
The therapy, which is given via infusion once a month, will be marketed under the name Kisunla.
Lilly noted that the treatment will cost $12,522 over six months and $32,000 per year. The 12-month cost includes 13 infusions, while six-month cost assumes six.
A U.S. FDA advisory panel in June unanimously endorsed the drug as effective.
Kisunla will compete against Biogen (BIIB) and Eisai (OTCPK:ESALF)(OTCPK:ESAIY) Leqembi (lecanemab).
This is breaking news…more to come